中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

93 records (took 0.024 seconds)

    ΣΥΝΔΥΑΣΜΟΙ ΓΙΑ ΘΕΡΑΠΕΙΑ HCV
    62.
    发明专利
    ΣΥΝΔΥΑΣΜΟΙ ΓΙΑ ΘΕΡΑΠΕΙΑ HCV 未知

    公开(公告)号：CY1110176T1

    公开(公告)日：2015-01-14

    申请号：CY091100274

    申请日：2009-03-10

    Applicant: VERTEX PHARMA

    Inventor： TUNG ROGER D ,  CHANDORKAR GURUDATT ,  PERNI ROBERT B

    IPC: A61K45/00 ,  A61K31/7056 ,  A61K38/21 ,  A61K45/06

    Abstract: Ηπαρούσαεφεύρεσηαφοράτηνσυν-χορήγησηενόςαναστολέαπρωτεάσης NS3/4A ιούΗπατίτιδας C καιενόςαναστολέαμονο-οξυγενάσηςκυτοχρώματοςΡ450. Οσυνδυασμόςδρααλληλεπιδρώνταςμετονκύκλοζωήςτουιούηπατίτιδας C καιεπομένωςείναιχρήσιμοςωςμιααντι-ιϊκήθεραπεία. Έτσι, οσυνδυασμόςμπορείναχρησιμοποιείταιγιατηνθεραπείαή πρόληψημολύνσεωνηπατίτιδας C σεασθενείς. Ηεφεύρεσηεπίσηςαφοράσυνθέσειςπουπεριλαμβάνουντονσυνδυασμόαναστολέων. Ηεφεύρεσηεπίσηςαφοράκιτκαιφαρμακευτικέςσυσκευασίεςπουπεριλαμβάνουνέναναναστολέαπρωτεάσης NS3/4A ιούηπατίτιδας C καιένααναστολέαμονο-οξυγενάσηςκυτοχρώματοςΡ450. Ηεφεύρεσηεπίσηςαφοράμεθόδουςπαρασκευήςαυτώντωνσυνθέσεων, συνδυασμών, κιτκαισυσκευασιών.

    Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease
    63.
    发明专利
    Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease 未知

    公开(公告)号：AU2012202822A1

    公开(公告)日：2012-06-07

    申请号：AU2012202822

    申请日：2012-05-15

    Applicant: VERTEX PHARMA

    Inventor： COTTRELL KEVIN M ,  DEININGER DAVID D ,  FARMER LUC J ,  PITLIK JANOS ,  PERNI ROBERT B ,  COURT JOHN J

    IPC: C07K5/02 ,  C07K7/02 ,  C07K14/18

    Abstract: The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

    Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease
    64.
    发明专利
    Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease 未知

    公开(公告)号：AU2011203054A1

    公开(公告)日：2011-08-11

    申请号：AU2011203054

    申请日：2011-06-23

    Applicant: VERTEX PHARMA

    Inventor： FARMER LUC J ,  PERNI ROBERT B ,  RAO BHISETTI GOVINDA ,  WILSON KEITH P

    IPC: C07D403/12 ,  A61K31/401 ,  A61K31/4155 ,  A61K31/425 ,  A61K31/4965 ,  C07D417/12

    Abstract: Abstract The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt, or mixtures thereof, that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use of for administration to a patient suffering from HCV infection and processes for preparing the compounds. The invention also relates to methods of treating HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention. R1, RR, 2 0 0

    INHIBIDORES DE SERINA-PROTEASAS.
    66.
    发明专利
    INHIBIDORES DE SERINA-PROTEASAS. 未知

    公开(公告)号：MX2009009176A

    公开(公告)日：2009-09-28

    申请号：MX2009009176

    申请日：2008-02-20

    Applicant: VERTEX PHARMA

    Inventor： FARMER LUC ,  PERNI ROBERT B ,  MAXWELL JOHN ,  BETHIEL RANDY SCOTT ,  JACOBS DYLAN ,  COTTRELL KEVIN ,  HALAS SUMMER

    IPC: C07D487/10 ,  A61K31/00 ,  A61P31/12 ,  C07D498/10

    Abstract: La presente invención se refiere a compuestos que inhiben la actividad de serina-proteasas, particularmente la actividad de la proteasa NS3-NS4A del virus de hepatitis C. como tales, actúan al interferir con el ciclo de vida del virus de hepatitis C y también son útiles como agentes antivirales. La invención se refiere adicionalmente a composiciones que comprenden estos compuestos ya sea para el uso ex vivo o para la administración de un paciente que padece de infección de HCV. La invención también se refiere a métodos para tratar una infección de HCV en el paciente al administrar una composición que comprende un compuesto de esta invención.

    67.
    发明专利
    未知

    公开(公告)号：DE602004018363D1

    公开(公告)日：2009-01-22

    申请号：DE602004018363

    申请日：2004-10-27

    Applicant: VERTEX PHARMA

    Inventor： TUNG ROGER D ,  CHANDORKAR GURUDATT ,  PERNI ROBERT B

    IPC: A61K45/00 ,  A61K31/7056 ,  A61K38/21 ,  A61K45/06

    Abstract: The present invention relates to co-administering a Hepatitis C virus NS3/4A protease inhibitor and a cytochrome P450 monooxygenase inhibitor. The combination acts by interfering with the life cycle of the hepatitis C virus and is therefore useful as an antiviral therapy. As such, the combination may be used for treating or preventing Hepatitis C infections in patients. The invention also relates to compositions comprising the combination of inhibitors. The invention also relates to kits and pharmaceutical packs comprising a Hepatitis C virus NS3/4A protease inhibitor and a cytochrome P450 monooxygenase inhibitor. The invention also relates to processes for preparing these compositions, combinations, kits, and packs.

    69.
    发明专利
    未知

    公开(公告)号：AT416789T

    公开(公告)日：2008-12-15

    申请号：AT04810032

    申请日：2004-10-27

    Applicant: VERTEX PHARMA

    Inventor： TUNG ROGER D ,  CHANDORKAR GURUDATT ,  PERNI ROBERT B

    IPC: A61K45/00 ,  A61K31/7056 ,  A61K38/21 ,  A61K45/06

    Abstract: The present invention relates to co-administering a Hepatitis C virus NS3/4A protease inhibitor and a cytochrome P450 monooxygenase inhibitor. The combination acts by interfering with the life cycle of the hepatitis C virus and is therefore useful as an antiviral therapy. As such, the combination may be used for treating or preventing Hepatitis C infections in patients. The invention also relates to compositions comprising the combination of inhibitors. The invention also relates to kits and pharmaceutical packs comprising a Hepatitis C virus NS3/4A protease inhibitor and a cytochrome P450 monooxygenase inhibitor. The invention also relates to processes for preparing these compositions, combinations, kits, and packs.

Patent Agency Ranking